Cardiologia Croatica, Vol. 7 No. 3-4, 2012.
Stručni rad
Atorvastatin treatment meets new European recommendations for the treatment of dyslipidemias.
Jana Golob
; Krka, d. d., Novo mesto, Slovenija
Sanja Brus
; Krka, d. d., Novo mesto, Slovenija
Mateja Grošelj
; Krka, d. d., Novo mesto, Slovenija
Breda Barbič-Žagar
orcid.org/0000-0002-1173-7361
; Krka, d. d., Novo mesto, Slovenija
Sažetak
Cardiovascular disease (CVD) still remains the leading cause of global mortality and causes nearly half of all deaths in Europe. Research shows that among many risk factors contributing to the development of CVD, dyslipidemia is one of the most significant. In August 2011, the European Society of Cardiology and the European Atherosclerosis Society released new guidelines for the management of patients with dyslipidemias, which consider low LDL cholesterol levels still as the primary treatment target. The guidelines recommend physicians prescribe statin therapy up to the highest dose possible or the highest tolerable dose to reach the target LDL cholesterol level. Several clinical studies confirmed the efficacy and safety of atorvastatin in clinical practice in a wide range of patients. The Anglo Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm (ASCOT-LLA) has demonstrated that reductions in major cardiovascular events with atorvastatin may contribute to long-term benefits on all-cause mortality. Krka is dedicated to continuously evaluate the efficacy and safety of its products.
Ključne riječi
LDL cholesterol; guidelines; atorvastatin
Hrčak ID:
84519
URI
Datum izdavanja:
3.3.2012.
Posjeta: 2.991 *